Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) – Equities researchers at Zacks Research lowered their FY2022 earnings per share estimates for Halozyme Therapeutics in a research report issued on Monday, September 19th. Zacks Research analyst I. Bandyopadhyay now anticipates that the biopharmaceutical company will earn $1.99 per share for the year, down from their previous forecast of $2.01. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $1.93 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ Q4 2022 earnings at $0.53 EPS, Q1 2023 earnings at $0.65 EPS, Q2 2023 earnings at $0.68 EPS, Q3 2023 earnings at $0.74 EPS, Q4 2023 earnings at $0.72 EPS, FY2023 earnings at $2.79 EPS, Q1 2024 earnings at $0.87 EPS, Q2 2024 earnings at $1.00 EPS and FY2024 earnings at $3.67 EPS.
Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.47 by $0.06. The company had revenue of $152.37 million for the quarter, compared to analysts’ expectations of $156.00 million. Halozyme Therapeutics had a return on equity of 101.73% and a net margin of 75.11%. The business’s revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 earnings per share.
Halozyme Therapeutics Price Performance
Halozyme Therapeutics stock opened at $40.28 on Wednesday. The business’s 50-day simple moving average is $44.31 and its 200 day simple moving average is $43.05. The stock has a market cap of $5.55 billion, a price-to-earnings ratio of 15.92, a P/E/G ratio of 0.70 and a beta of 1.25. Halozyme Therapeutics has a 12-month low of $31.36 and a 12-month high of $52.98. The company has a quick ratio of 2.23, a current ratio of 2.72 and a debt-to-equity ratio of 3.91.
Hedge Funds Weigh In On Halozyme Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HALO. First Horizon Advisors Inc. boosted its holdings in Halozyme Therapeutics by 188.8% during the second quarter. First Horizon Advisors Inc. now owns 722 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 472 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in Halozyme Therapeutics by 223.6% during the second quarter. Meeder Asset Management Inc. now owns 741 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 512 shares during the last quarter. Brown Brothers Harriman & Co. bought a new position in Halozyme Therapeutics during the second quarter worth about $35,000. San Luis Wealth Advisors LLC bought a new position in Halozyme Therapeutics during the first quarter worth about $36,000. Finally, Selective Wealth Management Inc. acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $44,000. Institutional investors own 91.72% of the company’s stock.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.